Myeloperoxidase, a new biomarker of Inflammation...
In the defence mechanism of the polymorph nuclear leukocytes, myeloperoxidase and other enzymes contained in primary granules destroy microorganisms and debris within the phagocytic vacuole of the cell.
But in many inflammatory situations, MPO is released into an extra cellular medium where its measurement can be used as an index of neutrophil activation and a marker of oxidative stress.
Furthermore, involvement of MPO has been described as a strong prognostic biomarker in cardiovascular diseases, and its implication has been proved in numerous diseases such as gastrointestinal diseases, cystic fibrosis and COPD.
Finally, it has been shown that MPO might be involved in several joint diseases including rheumatoid arthritis and osteoarthritis.
ZenTech has patented the SIEFED MPO determination under the name "Method and kit for the measurement of neutrophile cell activation" (WO 2005/075986).
code : E-HB-96 intended use : For the quantitative determination of human Myeloperoxidase method : ELISA sample size : 25 µl sample type : EDTA plasma incubations : 2 h/37°C+ 15 min/37 °C calibration range : 0-40 ng/mL controls included : 2 level automation : yes test/kit : 96 wells info : Product Info